Knockdown of GLUT4 was shown to induce metabolic reprogramming and decrease viability of breast cancer MCF-7 and MDA-MB-231 cells, and both GLUT1 and GLUT4 have been suggested as prognostic and therapeutic targets in breast cancers [136,137]. Here, SLC2A4 is linked to breast carcinoma.